| Bioactivity | Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment[1][2]. |
| Invitro | Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC) contributes to the separation of IR PCOS and control groups. Significant decrease in the levels of phosphocholines (PCs) and lyso PC (18:2), and increase in trilauric glyceride level are observed in the plasma of IR PCOS[1].Lysophosphatidylcholine (LPC), a major class of glycerophospholipids in human plasma, are implicated in inflammation, insulin resistance, obesity, and type 2 diabetes[2]. |
| Name | Lysophosphatidylcholine 18:2 |
| CAS | 22252-07-9 |
| Formula | C26H50NO7P |
| Molar Mass | 519.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
Lysophosphatidylcholine 18:2
CAS: 22252-07-9 F: C26H50NO7P W: 519.65
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker ident
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.